Sanofi CEOs past and present are in line for big payouts after yesterday's annual meeting, as resolutions passed to line the pockets of ousted skipper Chris Viehbacher and new replacement Olivier Brandicourt. But shareholders aren't necessarily thrilled about it, and investor advisory groups aren't, either.
Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor.
GlaxoSmithKline is facing sluggish sales in the U.S. and revenue growth that falls behind that of its Big Pharma rivals, not to mention scrutiny for CEO Andrew Witty. So Philip Hampton will have his work cut out for him as he steps into his new role as the company's chairman and attempts to revive the company's lagging fortunes.
Drugmakers may be willing to get on board with patent reform, a process they've in the past been blamed for holding up. But first, they have a very clear condition: Congress must help them thwart pharma patent challenger Kyle Bass.
Generics makers have been champing at the bit to get a copy out of Teva's Copaxone, the best-selling multiple sclerosis med that generated $4.2 billion in revenue last year. But according to Momenta CEO Craig Wheeler, his company's version--a joint effort with partner Sandoz, Novartis' generics unit--may be the only knockoff around for a while.
Cancer drug pricing is turning more and more heads, especially as critical payers threaten a crackdown in the oncology field. And there's a reason for all the hullaballoo: Spending on oncology meds is increasing rapidly, new IMS numbers show.
WuXi Biologics is embarking on construction of what will be the biggest biologics plant in China once it's completed--an event the company expects by the end of next year.
As payers continue to flex their drug-pricing muscles, it's more important for drugmakers to land on their good sides--especially as companies prepare to roll pricey treatments onto the market. And pharma execs are taking note.
Expecting demand for its hemophilia products to grow, diabetes drug specialist Novo Nordisk is kicking off construction of a $225 million plant at its extensive production site in Kalundborg.
Mylan may be demanding more than $100 per share from suitor Teva if it wants to talk takeover. But for itself--and its executives--its expectations aren't nearly that high.
New numbers on federal drug spending may say something about prescribing patterns for Medicare patients. Perhaps too many scripts for branded Nexium, when a generic stomach acid reducer might do, for instance.
Pfizer's Viagra sales may be suffering from generic rivals in Europe. But the brand is still going gangbusters in China, helping to soften the blow.
Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.
Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.
It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.
An Express Scripts unit agreed to settle claims with the U.S. Department of Justice that it participated in a scheme with Novartis that ended in improper government reimbursements. And if the DOJ has its way, the settlement could lead to more legal action against Novartis in a separate suit.
GlaxoSmithKline CEO Andrew Witty recently said slow-starting respiratory newcomer Breo was finally gaining some market traction. And now, it has a new asthma indication the company hopes can help speed things along.
Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.
When Vyvanse in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake in an extra $200 million to $300 million. Shire is already making its way there, it said Thursday, and the new sales helped the company notch a Q1 profit beat.
Johnson & Johnson said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity in jeopardy. But the company also said it would appeal, a process that could take years.